Skip to main content
. 2020 Sep 3;6(10):1–10. doi: 10.1001/jamaoncol.2020.3370

Figure 2. Kaplan-Meier Estimates of Overall Survival According to Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS).

Figure 2.

A, Overall survival in the PD-L1 CPS of 1 or greater population for pembrolizumab vs chemotherapy. B, Overall survival in the PD-L1 CPS of 10 or greater population for pembrolizumab vs chemotherapy. C, Overall survival in the PD-L1 CPS of 1 or greater population for pembrolizumab plus chemotherapy vs chemotherapy. D, Overall survival in the PD-L1 CPS of 10 or greater population for pembrolizumab plus chemotherapy vs chemotherapy. Tick marks represent data censored at the last time the patient was known to be alive.